Eiko LifeSciences Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	44.96	21.06	7.52	7.69	7.06
Depreciation & Amortization	10.16	7.37	6.63	6.33	5.62
Loss (Gain) From Sale of Assets	-	-0	-	-	-
Loss (Gain) From Sale of Investments	-	-0.15	-	-0.32	-
Loss (Gain) on Equity Investments	-0.53	-	-	-	-
Other Operating Activities	5.01	-2.25	1.59	-2.44	-1.53
Change in Accounts Receivable	-94.32	23.48	-60.28	-25.43	-11.48
Change in Inventory	18.02	-23.89	-24.78	45.5	-53.94
Change in Accounts Payable	92.45	19.34	3.35	-3.03	-5.47
Change in Other Net Operating Assets	-52.92	-15.72	-4.82	13.94	-17.54
Operating Cash Flow	22.84	29.24	-70.8	42.24	-77.27
Operating Cash Flow Growth	-21.89%	-	-	-	-
Capital Expenditures	-	-102.91	-3.47	-2.25	-1.55
Investment in Securities	-80.87	-31.22	-39.64	2.1	-0.03
Other Investing Activities	-5.75	19.69	37.62	8.89	6.42
Investing Cash Flow	-86.62	-114.45	-5.49	8.75	5.92
Long-Term Debt Issued	10.48	27.63	-	-	27.95
Total Debt Issued	10.48	27.63	-	-	27.95
Long-Term Debt Repaid	-	-	-	-45.53	-
Total Debt Repaid	-	-	-	-45.53	-
Net Debt Issued (Repaid)	10.48	27.63	-	-45.53	27.95
Issuance of Common Stock	74.94	43.46	205.05	-	9.5
Other Financing Activities	-3.3	-1.54	-1.42	-1.5	-4.64
Financing Cash Flow	82.12	69.56	203.62	-47.04	32.8
Miscellaneous Cash Flow Adjustments	-	-0	-0	0	-
Net Cash Flow	18.34	-15.65	127.34	3.95	-38.55
Free Cash Flow	22.84	-73.67	-74.26	39.99	-78.82
Free Cash Flow Margin	4.25%	-19.56%	-26.59%	21.83%	-31.02%
Free Cash Flow Per Share	1.62	-5.65	-7.20	4.09	-10.09
Cash Interest Paid	-	1.59	1.42	1.5	4.64
Cash Income Tax Paid	-	3.09	0.34	-0.75	2.11
Levered Free Cash Flow	9.29	-78.93	-77.13	47.74	-92.58
Unlevered Free Cash Flow	11.35	-77.97	-76.25	48.67	-90.27
Change in Working Capital	-36.77	3.21	-86.53	30.98	-88.43

Source: S&P Global Market Intelligence. Standard template. Financial Sources.